Mandate

Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.

The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs. 

Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
  
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge. 

Related

Vinge advises Stride.VC in connection with its investment in Anotherblock

In 2022, Anotherblock launched a blockchain-based marketplace for music rights. The company has through its platform granted fans access to streaming rights from several known artists. The investment round is led by Stride.VC.
May 25, 2023

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.
May 22, 2023

Vinge advises Tele2 in connection with its notes issuance and tender offer

Vinge advises Tele2 AB (publ) in connection with its issuance of senior unsecured fixed rate notes in an amount of EUR 500 million and its parallel tender offer in respect of its previously issued notes due 2024.
May 22, 2023